Influvac Tetra is a new generation quadrivalent influenza vaccine that protects against 4 influenza strains, providing high efficacy, reducing complications and mortality rates. According to the latest studies, full seasonal influenza vaccination in children and adults may enhance resistance against SARS-CoV-2 and reduce the risk of severe progression of Covid-19.
Influvac Tetra is manufactured by Abbott – Netherlands, indicated for prevention of seasonal influenza caused by influenza virus belonging to two type A strains (H1N1, H3N2) and two type B strains (Yamagata, Victoria) in adults and children over 6 months of age, especially elderly people and individuals with underlying medical conditions.
DOSAGE OF INFLUVAC TETRA
Influvac Tetra is indicated for adults and children over 6 months of age. The use of Influvac Tetra must be based on official recommendations.
– Adults and children over 06 months of age: One dose of Influvac Tetra 0.5 ml. Subsequently, annual booster vaccination is recommended.
– Children under 9 years of age, not previously vaccinated against seasonal influenza: One dose of Influvac Tetra 0.5 ml. A second dose should be administered after 4 weeks.
Subsequently, annual booster vaccination is recommended.
– Infants under 6 months of age: Safety and efficacy data have not been established.
USE OF INFLUVAC TETRA IN PREGNANCY AND LACTATION
– Pregnant women Inactivated influenza vaccines may be used during all stages of pregnancy.
– Breastfeeding women Influvac Tetra can be administered to women during breastfeeding.
ROUTE OF ADMINISTRATION
Intramuscular injection or deep subcutaneous injection.
CONTRAINDICATIONS
– Hypersensitivity to the active substances, to any excipient, or to any component which may be present in trace amounts such as eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin.
– Patients/children with febrile illness or acute infection should postpone vaccination.
PRECAUTIONS
– Do not administer intravenously. Antibody response may be reduced in patients with endogenous or treatment-induced immunosuppression.
– As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following administration.
ADVERSE REACTIONS
– Local reactions: redness, pain, swelling, induration at injection site.
– Systemic reactions: fever, malaise, headache, sweating, myalgia, arthralgia.
– These adverse reactions usually disappear within 1–2 days without treatment.
INTERACTIONS
– If Influvac Tetra is administered concomitantly with other vaccines, injections should be given at different limbs. It should be noted that adverse reactions may increase.
– Immune response may be reduced in patients receiving immunosuppressive therapy.
– After influenza vaccination, false positive results have been observed in serological tests using ELISA methods to detect antibodies against HIV1, Hepatitis C, and particularly HTLV1. The Western Blot technique negates these false positive ELISA results. Such transient false positive reactions may be due to the IgM response induced by the vaccine.
STORAGE
– Influvac Tetra influenza vaccine must be stored at +2°C to +8°C (in a refrigerator).
– Do not freeze.
– Store in original packaging. Protect from light.
Further related documents available HERE
